SCHEMBL3315424

SCHEMBL3315424

O=c1[nH]ccc2cc(N[C@H]3CCN(CC4CC4)C3)ccc12

nearest known ligand 0.43

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
PRKACA P17612 3/20 0.43
PRKACG P22612 3/20 0.43
PRKACB P22694 3/20 0.43
ROCK1 Q13464 5/20 0.40
ROCK2 O75116 11/20 0.40
CCR2 P41597 3/20 0.40
OPRM1 P35372 1/20 0.39
OPRD1 P41143 1/20 0.39
OPRK1 P41145 1/20 0.39
KIT P10721 1/20 0.38
FLT3 P36888 1/20 0.38
MAP2K1 Q02750 1/20 0.38
JAK2 O60674 1/20 0.37
JAK1 P23458 1/20 0.37
TYK2 P29597 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3315430 1.00 PRKACA (0.43) PRKACAPRKACGPRKACBROCK1ROCK2
SCHEMBL3311544 0.95 PRKACA (0.41) PRKACAPRKACGPRKACBROCK1ROCK2
SCHEMBL3311535 0.95 PRKACA (0.41) PRKACAPRKACGPRKACBROCK1ROCK2
SCHEMBL3315481 0.94 ROCK2 (0.47) ROCK1ROCK2CCR2
SCHEMBL3315491 0.94 ROCK2 (0.47) ROCK1ROCK2CCR2
SCHEMBL3317132 0.92 ROCK1 (0.42) PRKACAPRKACGPRKACBROCK1ROCK2
SCHEMBL3314660 0.90 MAP2K1 (0.45) PRKACAPRKACGPRKACBROCK1ROCK2
SCHEMBL3314665 0.90 MAP2K1 (0.45) PRKACAPRKACGPRKACBROCK1ROCK2
SCHEMBL3316985 0.89 ROCK2 (0.46) ROCK1ROCK2CCR2
SCHEMBL3316992 0.89 ROCK2 (0.46) ROCK1ROCK2CCR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8748614-B2 Substituted isoquinoline and isoquinolinone derivatives SANOFI (FR) 2014-06-10 US disclosed
US-8748614-B2 Substituted isoquinoline and isoquinolinone derivatives SANOFI (FR) 2014-06-10 US disclosed
US-8748614-B2 Substituted isoquinoline and isoquinolinone derivatives SANOFI (FR) 2014-06-10 US disclosed
US-20100105650-A1 Substituted isoquinoline and isoquinolinone derivatives SANOFI-AVENTIS (FR) 2010-04-29 US disclosed
US-20100105650-A1 Substituted isoquinoline and isoquinolinone derivatives SANOFI-AVENTIS (FR) 2010-04-29 US disclosed
US-20100105650-A1 Substituted isoquinoline and isoquinolinone derivatives SANOFI-AVENTIS (FR) 2010-04-29 US disclosed
EP-2114920-A1 SUBSTITUTED ISOQUINOLINE AND ISOQUINOLINONE DERIVATIVES Sanofi-Aventis (FR) 2009-11-11 EP disclosed
WO-2008077552-A1 SUBSTITUTED ISOQUINOLINE AND ISOQUINOLINONE DERIVATIVES SANOFI-AVENTIS (FR) 2008-07-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100105650-A1 Substituted isoquinoline and isoquinolinone derivatives MYLK2, MYLK, MYLK3 PRKACA 1104/4885PRKACG 942/4885PRKACB 1091/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.